shutterstock_1211592892_hannakuprevich1
hannakuprevich / shutterstock
21 March 2019Big Pharma

Seven new drugs to join $1bn club by 2021, says Clarivate

Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.

The “ Cortellis Drugs to Watch” report, published on Wednesday, March 20, by IP services provider  Clarivate Analytics, identified drugs that had the potential to become blockbusters within five years.

A ‘blockbuster’ drug is defined by the common $1 billion annual sales milestone.

According to the report, six out of seven of the drugs will target diseases characterised by genetic disorders or excessive immune response.

The full list includes Upadacitinib by  AbbVie, Zolgensma by AveXis, Ultomiris by Alexion, Ar-101 by Aimmune Therapeutics, LentiGlobin by bluebird bio, and Skyrizi by Boehringer Ingelheim and Abbvie.

Roxadustat, another drug on the list, is by  AstraZeneca, FibroGen and Astellas.

The genetic disorders treated by the drugs include spinal muscular atrophy, rheumatoid arthritis, and peanut allergy.

Clarivate said this indicates a shift towards medicine targeting niche patient populations, “buoyed by strong collaborations between big and specialty pharma companies to develop these therapies”.

The report also highlighted the positive impact of strategies and incentives put in place by regulatory bodies across the world to encourage drug development for niche markets and unmet medical needs.

Mukhtar Ahmed, president of life sciences at Clarivate, said it was encouraging to see how these incentives along with new discoveries were positively impacting patients in underserved populations.

“This year’s Drugs to Watch report demonstrates the impact of regulators’ incentives, including accelerated reviews and tax breaks, on drug development that targets rare diseases,” he said.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Americas
12 February 2019   Global information company Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.

More on this story

Americas
12 February 2019   Global information company Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.